Names and pronunciation
(si-lo′do-seen) Rapaflo
Source page 1206
Loading InternPractice…
Individual generic drug information
Extracted information for silodosin only.
(si-lo′do-seen) Rapaflo
Source page 1206
Func. class.: Selective α1-adrenergic blocker, BPH agent
Source page 1206
Chem. class.: Sulfamoylphenethyl- amine derivative
Source page 1206
ACTION: Binds preferentially to α1A- adrenoceptor subtype located mainly in the prostate
Source page 1206
USES: Symptoms of benign prostatic hyperplasia (BPH)
Source page 1206
Extracted information for silodosin only.
CONTRAINDICATIONS: Hyper- sensitivity, renal failure, hepatic disease Precautions: Pregnancy, breastfeeding, children, females, geriatric patients, renal/ hepatic disease, hypotension, ocular sur- gery, orthostatic hypotension, prostate cancer, syncope
Source page 1206
SIDE EFFECTS CNS: Dizziness, headache, insomnia, syncope CV: Orthostatic hypotension EENT: Nasal congestion GI: Diarrhea GU: Abnormal ejaculation, urinary incontinence, priapism INTEG: Rash, pruritus, allergic reactions
Source page 1206
INTERACTIONS Increase: silodosin effect—CYP3A4 inhibi- tors (clarithromycin, itraconazole, ritona- vir, antiretroviral protease inhibitors, aprepitant, chloramphenicol, conivaptan, dalfopristin, danazol, delavirdine, efavirenz, fosaprepitant, fluconazole, fluvoxaMINE, imatinib, isoniazid, miFEPRIStone, nefazo- done, tamoxifen, telithromycin, troleando- mycin, voriconazole, zileuton, zafirlukast); P-gb inhibitors Drug/Food Increase: silodosin effect—grapefruit juice Drug Lab/Test Increase: LFTs
Source page 1206
Extracted information for silodosin only.
DOSAGE AND ROUTES BPH Adult: PO 8 mg daily with a meal Renal dose • Adult: PO CCr 30-49 mL/min, 4 mg/ day; CCr <30 mL/min, not recommended
Source page 1206
Available forms: Cap 4, 8 mg
Source page 1206
Administer: • Give with meal at same time each day • Cap may be opened and sprinkled on applesauce, if unable to swallow, use water after applesauce • Store at room temperature; protect from light and moisture
Source page 1206
Extracted information for silodosin only.
Assess: • Prostatic hyperplasia: change in uri- nary patterns at baseline and throughout treatment; testing for prostate cancer be- fore administration is recommended • BUN, uric acid, urodynamic studies (urinary flow rates, residual volume), CCr; contraindicated in CCr <30 mL/min; I&O ratios, weight daily, edema, report weight gain or edema • B/P (sitting, standing) during initial treatment; monitor for orthostatic hy- potension; increased risk in elderly >65 yr • Pregnancy/breastfeeding: not indi- cated for women
Source pages 1206, 1207
Evaluate: • Therapeutic response: decreased symptoms of BPH Teach patient/family • Not to drive or operate machinery until effect is known; orthostatic hypotension occasionally occurs after first dose • Not to use with grapefruit juice • To take with same meal each day; contents of capsule may be sprinkled on room-temperature applesauce if con- sumed within 5 min; follow with 8 oz cool water HIGH ALERT
Source page 1207
CLINICAL CONSIDERATIONS
Source page 1206
Extracted information for silodosin only.
PHARMACOKINETICS Decreased absorption with high-fat/ high-calorie meal, half-life 13.3 hr of metabolite 24 hr, metabolized in liver extensively by CYP3A4, UGT2B7, excreted via urine, feces (55%) exten- sively protein bound (97%), onset rapid, peak up to 24 hr, duration up to 24 hr
Source page 1206
Filter the extracted dose blocks for this individual drug.
BPH Adult: PO 8 mg daily with a meal Renal dose
• Adult: PO CCr 30-49 mL/min, 4 mg/ day; CCr <30 mL/min, not recommended
Candidate age grouping · source page 1206